Current Clinical Trials on the Use of Ceftaroline in the Pediatric Population

The rate of antibiotic resistance in children continues to rise requiring the use of new antibiotics. Ceftaroline fosamil, a newer-generation cephalosporin, was recently approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in chi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2017-07, Vol.37 (7), p.625-634
Main Authors: Corey, Adam, So, Tsz-Yin
Format: Article
Language:English
Subjects:
Adult
Adults
Anti-Bacterial Agents - administration & dosage
Antibiotics
Ceftaroline
Cephalosporins - administration & dosage
Child
Clinical trials
Community-Acquired Infections - drug therapy
Drug dosages
Drug resistance
FDA approval
Humans
Internal Medicine
Internet
Laboratories
Medicine
Medicine & Public Health
Meningitis
Methicillin-Resistant Staphylococcus aureus - drug effects
National libraries
Pediatrics
Penicillin
Pharmacology/Toxicology
Pharmacotherapy
Pneumonia
Population
Review Article
Sepsis
Sepsis - drug therapy
Skin
Staphylococcus infections
Streptococcus infections
Streptococcus pneumoniae - drug effects
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rate of antibiotic resistance in children continues to rise requiring the use of new antibiotics. Ceftaroline fosamil, a newer-generation cephalosporin, was recently approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in children aged >2 months. Ceftaroline provides coverage against staphylococcal and streptococcal infections, including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae . Pediatric dosing differs from adult dosing, but it maintains a similar pharmacokinetic profile and offers similar efficacy in terms of time above the minimum inhibitory concentration as compared to the adult population. The clinical safety and efficacy of this antibiotic has been assessed in three pediatric clinical trials that led to its approval by the US Food and Drug Administration, and each trial is described within this review. This article will also discuss the ongoing trials assessing the possibility of expanding the indications of this antibiotic to late-onset sepsis, meningitis and osteomyelitis in the pediatric population.
ISSN:1173-2563
1179-1918
DOI:10.1007/s40261-017-0523-2